A trial for an Ebola vaccine is set to commence in the Democratic Republic of Congo, following a warning from the World Health Organization (WHO) regarding the rapid increase in infections. The ongoing conflict between Congolese government forces and rebel groups, including the M23 alliance, complicates efforts to contain the outbreak. The M23 alliance, which previously captured key cities, has claimed to administer its own Ebola response in areas under its control and declared its territories Ebola-free in late June.
The current outbreak involves the Bundibugyo species of Ebola, a rare strain with only two previous known occurrences. Symptoms of the disease, which can appear suddenly between two and 21 days after infection, include fever, headache, and tiredness, mirroring those of the flu or malaria. As the illness progresses, individuals may experience vomiting and diarrhea, potentially leading to organ failure. The virus spreads through contact with infected bodily fluids such as blood or vomit.
According to the WHO, approximately half of the 2,500 recorded deaths from Ebola have occurred within the last 20 days, underscoring the urgency of the situation. The introduction of a vaccine trial in this challenging environment highlights the complexities of public health interventions in conflict zones.